Revolution Medicines, Inc. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
Revolution Medicines, Inc. (RVMD) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $69.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2025-11-05
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $69.00K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $336.00K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $603.00K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $267.00K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2025-09-30 | $69.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $336.00K 10-Q · filed 2025-08-06 |
| 2025-03-31 | $603.00K 10-Q · filed 2025-05-07 |
| 2024-09-30 | $267.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $535.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $802.00K 10-Q · filed 2024-05-08 |
| 2023-09-30 | $268.00K 10-Q · filed 2023-11-06 |
| 2023-06-30 | $535.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $802.00K 10-Q · filed 2023-05-08 |
| 2022-09-30 | $268.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $535.00K 10-Q · filed 2022-08-09 |
| 2022-03-31 | $802.00K 10-Q · filed 2022-05-09 |
| 2021-09-30 | $266.00K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $533.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $801.00K 10-Q · filed 2021-05-10 |
| 2020-09-30 | $266.00K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $533.00K 10-Q · filed 2020-08-10 |
| 2020-03-31 | $800.00K 10-Q · filed 2020-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |